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108Background: Azathioprine is efficacious in the treatment of severe childhood atopic dermatitis; however,
robust data on adverse effects in this population are lacking.Objective: We sought to assess adverse effects of azathioprine treatment in a pediatric atopic dermatitis
cohort, and make recommendations for monitoring based on these data.Methods: Blood test results for all 82 children prescribed oral azathioprine for atopic dermatitis in our
department between 2010 and 2012 were collated prospectively, and clinical notes were reviewed
retrospectively.Results: Mean age at commencing azathioprine was 8.3 years (SEM 0.4). Mean maximum doses were
2.4 mg/kg (SEM 0.1) and 1.5 mg/kg (SEM 0.1) for normal and reduced serum thiopurine-S-
methyltransferase levels, respectively. Adverse effects on blood indices occurred in 34 of 82 patients
(41%), with pronounced effects in 18 of 82 (22%) after a median time of 0.4 years. Two patients stopped
therapy as a result of abnormal blood indices. Clinical adverse effects occurred in 16 of 82 (20%), two
resulting in cessation of therapy. Incidence of adverse effects was unaffected by age, sex, thiopurine-S-
methyltransferase level, and drug dose on multivariate regression.Limitations: Comparison with other studies is limited by varying definitions of adverse effects.Conclusion: Oral azathioprine was associated with few pronounced adverse effects for the duration
of use and dosage in this cohort. Recommendations for monitoring are made. ( J Am Acad Dermatol
2015;72:108-14.)
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AD: atopic dermatitis
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Fuggle et al 109score.1,2 A randomized comparisonwithmethotrexate
showed comparable efficacy.3 Nonrandomized
studies of 484 and 245 pediatric patients reported
significant improvement in 88% and 61% of cases,
respectively. A series of 12 children treated with
azathioprine for recalcitrant AD reported improve-
ment in 92% of cases.6CAPSULE SUMMARY
d There are no published guidelines for
monitoring adverse effects of
azathioprine treatment in pediatric
atopic dermatitis
d Azathioprine was associated with
frequent mild and infrequent
pronounced adverse effects in this
cohort of 82 children with severe atopic
dermatitis
d Recommendations for laboratory
monitoring of azathioprine therapy are
offered based on our experienceProspective studies in
adults have found a low inci-
dence of adverse effects
requiring cessation of AD
treatment, all of which were
reversible after reduction
or cessation of therapy.1-3,7
Similar findings are reported
in pediatric AD studies.4-6
Azathioprine is meta-
bolized by the enzyme
thiopurine-S-methyltransfer-
ase (TPMT) and causes
immunosuppression via in-
hibition of the lymphocyte
cell cycle.8 Serum levels of
TPMT activity vary due to
DNA sequence polymor-
phisms, with normal levels in 80%, low in 10%,
high in 9%, and undetectable in 0.5%9 of the
population. Patients with lower TPMT levels are
routinely commenced on a lower dose of azathi-
oprine to reduce the risk of adverse effects.4,10-12
Known adverse effects of azathioprine include
gastrointestinal symptoms, nausea, fatigue and mal-
aise, along with myelosuppression, lymphopenia,11
neutropenia,12,13 and hepatotoxicity.14 Guidelines
for adults recommend monitoring of liver enzymes
and complete blood cell count (CBC), ‘‘at least
3-monthly once on a stable dose, and more
frequently before stabilization.’’14 There are no
published guidelines for monitoring azathioprine
use in pediatric AD.
The aims of this study were to document
the timing and nature of adverse effects during
azathioprine treatment in a cohort of pediatric
patients with AD, and to suggest recommendations
for monitoring.
METHODS
Hospital pharmacy records were accessed to
ascertain the total number of children prescribed
azathioprine for AD during the period 2006 to
2012. Adverse effects were studied in detail in all
children prescribed oral azathioprine between
January 2010 and December 2012. This subset
was selected as all blood results from our depart-
ment, and primary and secondary care facilitiesinvolved in azathioprine monitoring, were collated
prospectively into a database from January 2010
onwards. Criteria for commencing azathioprine
were: (1) severe eczema affecting growth, quality
of life, or both; (2) failure of first- and second-line
therapies; and (3) biochemical evidence of normal
or carrier status TPMT level.Oral AZT was the first-line
systemic therapy for the
cohort studied because of
successful clinical experience
of this drug for pediatric AD in
our department. The dosage
was 2.0 to 3.5 mg/kg/d for
those with a normal TPMT
level. The lowest effective
dose was used, only increas-
ing within this range if clinical
response was suboptimal and
there were no adverse effects.
Because of delay in the onset
of action of azathioprine a
4- to 6-week bridging course
of oral prednisolone was rou-
tinely administered.Clinic notes were reviewed retrospectively to
record clinical adverse effects interfering with
normal activities, and to review management of
all adverse effects. Adverse effects in blood
indices were defined as hepatic transaminase
levels greater than 50 U/L, leukocyte count less
than 4 3 109/L, lymphocytes less than 1 3 109/L,
and neutrophils less than 1.5 3 109/L.
‘‘Pronounced adverse effects’’ were defined as
hepatic transaminase levels greater than 50 U/L,
lymphocytes less than or equal to 0.5 3 109/L,
and neutrophils less than 1.0 3 109/L. As this
study included only children who were pre-
scribed azathioprine, we do not have data on
whether there were patients who did not begin
therapy as a result of abnormal pretreatment
blood tests.
Outcome measures were adverse effects,
pronounced adverse effects, and clinical adverse
effects requiring alteration of therapy. Drug-
related variables were starting dose, maximum
dose, and time since commencing or increasing
the dose of azathioprine. Patient demographics
collected were age at commencing treatment,
sex, and TPMT level (normal or carrier). The
interaction of drug-related variables and patient
demographics on outcome measures was
modeled using multiple logistic regression, and
a Bonferroni correction applied for multiple
testing.
Table I. Clinical phenotype of the detailed atopic
dermatitis study cohort
Demographic N (%)
Males 54/82 (66)
Low TPMT 11/82 (13)
Diagnosis of asthma 31/82 (38)
Diagnosis of allergy 70/82 (85)
History of anaphylaxis 13/82 (16)
Raised total IgE 35/82 (43)
Family history of atopy 50/82 (61)
TPMT, Thiopurine-S-methyltransferase.
Table II. Details of 2 subgroups of adverse effects;
pronounced adverse effects on blood indices, and
clinical adverse effects possibly attributable to
azathioprine administration
Adverse effect N (%)
Abnormal complete blood cell count parameters 8 (10)
Elevated hepatic transaminases 11 (13)
Abnormal complete blood cell count and liver
enzymes
1 (1)
Cutaneous viral infection 10 (12)
Nausea 1 (1)
Lethargy 1 (1)
Indigestion 1 (1)
Possible myopathy (unconfirmed and lost to
follow-up)
1 (1)
Headache 1 (1)
Chest infection 1 (1)
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Study population
In all, 186 children (112 male) were prescribed
azathioprine for AD during the period 2006 to
2012 with a mean age at starting therapy of 9.40
years. The mean duration of use was 2.14 years
(780 days) with 4 patients lost to follow-up. There
were no irreversible or fatal adverse effects docu-
mented due to azathioprine. In the detailed study
period (2010-2012), 82 children (54 male) were
prescribed azathioprine for AD. The mean age at
commencing treatment was 8.3 years (SEM 0.4).
Eleven children (13%) had low levels of TPMT,
consistent with carrier status for TPMT poly-
morphisms. Detailed phenotypic information is
shown in Table I.
Abnormal laboratory results
Adverse effects on blood indices were seen in 33
of 82 patients (40%), 24 involving CBC, 11 involving
liver transaminases, and 2 involving both.
Pronounced effects on blood indices were seen in
18 of 82 (Table II). Of these, 9 of 18 required no
change in treatment other than a repeated blood test,
5 of 18 had brief cessation of therapy and a repeated
test before continuing treatment unchanged, 2 of 18
required a reduction in dose, and 2 of 18 ceased
therapy. The mean time to a pronounced adverse
effect after either commencing azathioprine or
increasing the dose was 0.46 years (SEM 0.11),
median 0.38 years (range 0.00-1.72 years).
Eight patients (10%) had a pronounced adverse
effect on CBC: 7 neutropenia and 1 lymphopenia. In
5 patients no action was required other than
continued monitoring, 2 required a brief cessation
of therapy and 1 required a reduction in dose. In 1
case, azathioprine was discontinued because of
recurrent neutropenia. Eleven patients (13%) had
abnormal liver transaminase levels. In 5 of 11, these
resolved spontaneously with no change in treatment
other than repeated blood testing, 4 of 11 had a brief
cessation of therapy before continuing, and 1 of 11
had a reduction in dose. In 1 patient therapy was
withdrawn because of recurrent elevation in
transaminase levels.
Clinical adverse effects
Clinical adverse effects were seen in 16 of 82
(20%) and were generally mild. Most common were
cutaneous viral infections (molluscum contagiosum
and viral warts) in 12%, with single cases of
nausea, lethargy, indigestion, asthma exacerbation,
unconfirmed possible myopathy (subsequently
lost to follow-up), headache, and recurrent chest
infections. Three patients ceased therapy afterclinical adverse effects. The first experienced
headaches two weeks after a dose increase, which
resolved when azathioprine was stopped. The
second had recurrent chest infections after the
second year of therapy (one occasion requiring
admission to hospital). The third had recurrent
herpes labialis.
Cessation of azathioprine due to adverse
effects
In total, 5 patients (6%) discontinued azathioprine
because of adverse effects: recurrent neutropenia
(1); persistently raised alanine aminotransferase (1);
headaches (1: stopped by parents); recurrent chest
infections (1); and recurrent herpes labialis (1).
Statistical analysis
On multiple logistic regression with Bonferroni
correction the odds ratio of having an adverse effect
on blood indices was unaffected by age, sex, TPMT
carrier status and the maximum dose reached, along
with any drug-related or patient demographic
Fig 1. Time to pronounced adverse effects that could be
attributable to azathioprine therapy, measured from the
start of azathioprine (if no change in dose since
commencing) or from the date of the most recent increase
in dose. Note the clustering of effects in the first 9 months.
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indices was skewed towards the start of treatment or
after a dosage increase (Fig 1).
DISCUSSION
In this cohort of pediatric patients with AD,
azathioprine treatment was associated with frequent
mild adverse effects and infrequent pronounced
adverse effects in blood indices. The majority
required little or no treatment alteration, although
they were monitored closely. The high number
of self-resolving abnormal results was likely a
result of unrelated intercurrent infections. Physician
assessment is important. Irreversible or fatal adverse
effects were not encountered in 186 children
prescribed azathioprine for AD in our department
in the last 8 years. However, such events have rarely
been reported.13
The overall pattern of adverse effects is compara-
ble with other studies of azathioprine treatment of
AD. In a recent randomized controlled trial
comparing azathioprine with methotrexate, 36%
and 77% of 22 adult patients receiving azathioprine
had abnormal liver transaminase levels and CBC,
respectively, but only 9% required withdrawal of
treatment and 9% necessitated a dose adjustment.3
Detailed comparison of hepatic transaminase levels
with other studies is hampered by varying definitions
of abnormality but the numbers reported are of a
similar order. We found pronounced hepatic trans-
aminase abnormalities (defined as[50 IU/L) in 13%of 82 prospectively collected patients, which is
similar to other pediatric AD studies (8%-21%4-6);
adult AD studies report 10% to 36%1-3 (Table III). It
has been suggested that adults with a normal to high
TPMT activity are at greater risk of azathioprine-
induced liver injury because of increased production
of toxic methylated thiopurine metabolites,11 but we
did not find any such association in this pediatric
cohort.
Neutropenia and lymphopenia were relatively
common. In pediatric AD studies rates of lympho-
penia vary from 1% to 43%,1,2 and neutropenia 5%; a
recent systematic review recorded an abnormal CBC
in 77% of patients.14 In a study of 52 adults with
inflammatory bowel disease, lymphopenia was
significantly associated with concurrent steroid treat-
ment at the start of azathioprine use.15 As our
patients were on systemic steroid treatment for the
initial weeks of azathioprine therapy, this potentially
contributed to the rate of mild lymphopenia.
Clinical adverse effects were cutaneous viral
infections (12%), nausea, lethargy, indigestion,
deterioration in asthma, unconfirmed possible
myopathy, headache, and recurrent chest infections.
Migraines and headaches have occurred in 4% to
12% of adult patients with AD on azathioprine.1,2
Respiratory tract infections have been reported in
10% to 13% of cases. Dermatologic manifestations
have included folliculitis in 5% and impetigo in 3%.1,2
In one pediatric population the rate of cutaneous
infection was significantly higher (57%).5 Nausea is a
well-recognized adverse effect in adult populations,
occurring in 51% of patients in one study.2 We
encountered only a single case of nausea (1%) after
one year of treatment and this was successfully
managed with a small reduction in dose.
It is interesting that in our subset of children for
whom detailed records were available twice as many
boys as girls received azathioprine for treatment of
AD. In a recent epidemiologic study of pediatric AD
in the United Kingdom, girls were more commonly
affected than boys but boys were less likely to apply
emollients.16 It may be that the sex difference
observed in our study is not a true difference
in severity, but related to difficulty implementing
first- and second-line therapies. There were no
differences in adverse effects between the sexes.
Our current practice for monitoring azathioprine
therapy is as follows (Fig 2):
d Pretreatment: Blood tests as per Fig 2. Advice on
sun avoidance and sun protection. The presence
of any cutaneous viral infections is recorded. If
the TPMT level is undetectable, azathioprine is
not prescribed. If a polymorphism carrier level is
detected an appropriate reduction in dosage
Table III. Comparison of previous publications of azathioprine safety in treatment of atopic dermatitis
Reference Population n
Hepatic
transaminase AEs CBC AEs Clinical AEs
Patients withdrawn
because of AEs
Murphy and Atherton,4 2002 Pediatric 48 5 (10.4%) Macrocytosis e 3 (6.3%)
Transient lymphopenia e 15 (31%)
Transient thrombocytopenia e 1 (2.1%)
GI upset e 1 (2.1%)
Eczema herpeticum e 1 (2.1%)
Hypersensitivity e 1 (2.1%)
Nil
Berth-Jones et al,1 2002 Adult 37 8 (10.4%) Lymphopenia e 1 (1.3%)
Lymphopenia and mild neutropenia e 1 (1.3%)
GI upset e 14 (18%)
URTI e 5 (6.5%)
Folliculitis e 2 (2.6%)
4 (10.8%)
Murphy and Atherton,10 2003 Pediatric 2 Nil
Meggitt et al,2 2006 Adult 41 ALT[15%
ULN e 4 (10%)
ALT[50%
ULN e 2 (5%)
[1 Episode neutropenia e 2 (5%)
[1 Episode mild lymphopenia
(1-1.5 3 109/L) e 18 (43%)
[1 Episode moderate lymphopenia
(0.5-1 3 109/L) e 10 (24%)
Nausea e 21 (51%)
Headache e 5 (12%)
Abdominal pain e 4 (10%)
Lightheadedness e 3 (7%)
Cellulitis e 3 (7%)
LRTI e 2 (5%)
URTI e 2 (5%)
Malaise e 1 (2%)
6 (14.6%)
Waxweiler et al,5 2011 Pediatric 28 6 (21%) Cutaneous infection e 16 (57%)
GI effect e 8 (29%)
Schram et al,3 2011 Adult 22 8 (36%) 17 (77%) Infections e 14 (64%)
GI effects e 13 (59%)
AD exacerbation e 2 (9%)
9%
Caufield and Tom,6 2013 Pediatric 12 1 (8.3%) 1 (8.3%) Nil
AD, Atopic dermatitis; AE, adverse event; ALT, alanine aminotransferase; CBC, complete blood cell count; GI, gastrointestinal; LRTI, lower respiratory tract infection; ULN, upper limit of normal; URTI,
upper respiratory tract infection. J
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Fig 2. Recommendations for monitoring of blood indices during azathioprine use for atopic
dermatitis in children. HHV, Human herpesvirus; TPMT, thiopurine-S-methyltransferase; VZV,
varicella zoster virus.
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Local guidelines for varicella exposure are
followed.
d Standard blood monitoring of CBC and hepatic
transaminases at weeks 1, 3, and 7 after
commencing azathioprine, and every 3 months
thereafter, unless there is a breach of blood
parameters.
d A breach of blood parameters is defined as
neutrophil count less than 1.0, lymphocyte count
less than or equal to 0.5, or alanine aminotrans-
ferase greater than twice the upper limit of the
normal range for age. The latter we consider more
appropriate than an absolute value.
d For either a first breach in blood parameters, or
a new breach after regular blood tests (every
3 months) have been established, we recommend
maintaining the same dose of azathioprine and
repeating blood tests after 1 week. If repeated
investigations reveal normal findings, treatment is
continued unchanged.
d For a second breach of parameters, either in the
repeat blood tests after a first breach, or before
the regular bloods (every 3 months) are estab-
lished, azathioprine is withheld for a week and
then blood tests are repeated. If the repeated
results are normal, azathioprine is recommenced
but at a lower dose (reduced by 0.25 mg/kg ifnormal level of TPMT, reduced by 0.25-0.5 mg/kg
if low level of TPMT).
d For a third breach of parameters, either immedi-
ately after a second breach, or before the regular
blood tests (every 3 months) are established, the
senior clinician decides whether to discontinue
azathioprine.
d Whenever a dose adjustment is made or a
breach of parameters has occurred, the standard
monitoring cycle of blood tests is recommenced.
Assessment of posttreatment effects of azathio-
prine therapy for pediatric AD is outside the scope of
our study. The long-term safety profile is unknown,
and this fact should be discussed with families
before starting azathioprine. Azathioprine use is
associated with a range of hematologic, hepatotoxic,
clinical, and long-term carcinogenic adverse effects
including nonmelanoma skin cancer. As with any
systemic therapy, concerns have to be balanced
against the need to treat refractory eczema with its
attendant effects on longitudinal growth17-20 and
neurodevelopment.21
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